Modification of alternative splicing by antisense therapeutics - PubMed (original) (raw)
Review
Modification of alternative splicing by antisense therapeutics
Ryszard Kole et al. Oligonucleotides. 2004 Spring.
Abstract
Alternative splicing allows the production of several different proteins from a single pre-mRNA, resulting in an increased diversity of proteins derived from a relatively limited number of transcribed genes. Although it is necessary for normal development, alternative splicing and its aberrations are also implicated in disease states from thalassemia and cancer to neurodegenerative disorders. Techniques that trick the splicing machinery to alter the splicing pathways can be of high therapeutic value. Antisense technology, used mostly for RNA downregulation, recently has been adapted to alter the splicing process. The promise of this approach is now being realized as a result of chemical modification of oligonucleotides and improvements in their delivery in vivo.
Similar articles
- RNA splicing: disease and therapy.
Douglas AG, Wood MJ. Douglas AG, et al. Brief Funct Genomics. 2011 May;10(3):151-64. doi: 10.1093/bfgp/elr020. Brief Funct Genomics. 2011. PMID: 21628314 Review. - More than a messenger: Alternative splicing as a therapeutic target.
Black AJ, Gamarra JR, Giudice J. Black AJ, et al. Biochim Biophys Acta Gene Regul Mech. 2019 Nov-Dec;1862(11-12):194395. doi: 10.1016/j.bbagrm.2019.06.006. Epub 2019 Jul 2. Biochim Biophys Acta Gene Regul Mech. 2019. PMID: 31271898 Free PMC article. Review. - [Pre-mRNA alternative splicing in cancer: functional impact, molecular mechanisms and therapeutic perspectives].
Revil T, Shkreta L, Chabot B. Revil T, et al. Bull Cancer. 2006 Sep;93(9):909-19. Bull Cancer. 2006. PMID: 16980234 Review. French. - Modification of pre-mRNA splicing by antisense oligonucleotides.
Kole R. Kole R. Acta Biochim Pol. 1997;44(2):231-7. Acta Biochim Pol. 1997. PMID: 9360712 Review. - Control of alternative pre-mRNA splicing by RNA Pol II elongation: faster is not always better.
Nogués G, Kadener S, Cramer P, de la Mata M, Fededa JP, Blaustein M, Srebrow A, Kornblihtt AR. Nogués G, et al. IUBMB Life. 2003 Apr-May;55(4-5):235-41. doi: 10.1080/1521654031000119830. IUBMB Life. 2003. PMID: 12880204 Review.
Cited by
- Cell penetrating peptide conjugates of steric block oligonucleotides.
Lebleu B, Moulton HM, Abes R, Ivanova GD, Abes S, Stein DA, Iversen PL, Arzumanov AA, Gait MJ. Lebleu B, et al. Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):517-29. doi: 10.1016/j.addr.2007.09.002. Epub 2007 Oct 22. Adv Drug Deliv Rev. 2008. PMID: 18037527 Free PMC article. Review. - Current progress on aptamer-targeted oligonucleotide therapeutics.
Dassie JP, Giangrande PH. Dassie JP, et al. Ther Deliv. 2013 Dec;4(12):1527-46. doi: 10.4155/tde.13.118. Ther Deliv. 2013. PMID: 24304250 Free PMC article. Review. - Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron.
Singh NK, Singh NN, Androphy EJ, Singh RN. Singh NK, et al. Mol Cell Biol. 2006 Feb;26(4):1333-46. doi: 10.1128/MCB.26.4.1333-1346.2006. Mol Cell Biol. 2006. PMID: 16449646 Free PMC article. - The potential of antisense oligonucleotide therapies for inherited childhood lung diseases.
Martinovich KM, Shaw NC, Kicic A, Schultz A, Fletcher S, Wilton SD, Stick SM. Martinovich KM, et al. Mol Cell Pediatr. 2018 Feb 6;5(1):3. doi: 10.1186/s40348-018-0081-6. Mol Cell Pediatr. 2018. PMID: 29411170 Free PMC article. Review. - Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells.
Kotula JW, Pratico ED, Ming X, Nakagawa O, Juliano RL, Sullenger BA. Kotula JW, et al. Nucleic Acid Ther. 2012 Jun;22(3):187-95. doi: 10.1089/nat.2012.0347. Nucleic Acid Ther. 2012. PMID: 22703281 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources